Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Novel Therapy for Multidrug Resistant Gram Negative Infections in
Brittany A Rodriguez1,2, Jennifer E Girotto1,2,3, David P Nicolau4
1Department of Pharmacy, Connecticut Children's Medical Center, Hartford, CT 06102, United States.
Abstract:
The rise in Multidrug-resistant (MDR) infections has become a significant problem in both the developing countries and in the United States (U.S.). Specifically, MDR gram-negative infections are emerging, affecting not only adults but children as well. The specific gram-negative organisms that have been most concerning within the pediatric population include MDR P. aeruginosa, Enterobacteriaceae, and Acinetobacter spp. The increase in antimicrobial resistance rates is associated with various mechanisms with one of the most common being the production of beta-lactamases. Both Ceftazidime/Avibactam (CZA) and Ceftolozane/Tazobactam (C/T) are two recently approved antibiotics in the U.S. While both of these agents are inhibitors of beta-lactamase enzymes, there are differences between them that are important to understand. At this time, the data in children for these agents are extremely limited. The aim of this review is to describe the characteristics of these agents and their potential uses in pediatric patients.
Insights
Multidrug-resistant gram-negative infections are a growing concern in children. This review examines Ceftazidime/Avibactam and Ceftolozane/Tazobactam, new antibiotics for pediatric use, given limited current data.
Area of Science:
- Pediatric Infectious Diseases
- Antimicrobial Resistance
- Pharmacology
Background:
- Multidrug-resistant (MDR) infections, particularly MDR gram-negative bacteria, pose a significant global health threat.
- Pediatric populations are increasingly affected by MDR organisms like P. aeruginosa, Enterobacteriaceae, and Acinetobacter spp.
- Beta-lactamase production is a primary mechanism driving antimicrobial resistance.
Purpose of the Study:
- To review the characteristics of Ceftazidime/Avibactam (CZA) and Ceftolozane/Tazobactam (C/T).
- To explore the potential applications of CZA and C/T in pediatric patients.
- To address the limited data available on these agents in children.
Main Methods:
- Literature review of CZA and C/T.
- Analysis of beta-lactamase inhibition mechanisms.
- Examination of existing pediatric data and clinical trial information.
Main Results:
- CZA and C/T are novel beta-lactam/beta-lactamase inhibitor combinations.
- Both agents target specific MDR gram-negative pathogens.
- Current pediatric data for CZA and C/T are scarce, necessitating further research.
Conclusions:
- CZA and C/T represent important therapeutic options for MDR gram-negative infections.
- Understanding their distinct properties is crucial for effective clinical application in children.
- Further pediatric studies are essential to guide optimal use of these antibiotics.
Related Concept Videos
Gram-negative Bacterial Protein Secretion Systems
Negative Regulator Molecules
Positive, Negative, and Zero Work
Resistivity
Resistance
Gene Therapy


